Borrego-Jimenez Pedro-Santiago, Padilla-Fernandez Bárbara-Yolanda, Valverde-Martinez Sebastián, Garcia-Sanchez Maria-Helena, Rodriguez-Martin Maria-de-la-O, Sanchez-Conde Maria-Pilar, Flores-Fraile Maria-Carmen, Marquez-Sanchez Magaly, Flores-Fraile Javier, Perán-Teruel Miguel, Mirón-Canelo José-Antonio, García-Cenador Maria-Begoña, Lorenzo-Gómez María-Fernanda
Department of Surgery, University of Salamanca, 37001 Salamanca, Spain.
Physiotherapy Department of Institute of Applied Technology, Abu Dhabi 3798, UAE.
J Clin Med. 2020 Oct 15;9(10):3310. doi: 10.3390/jcm9103310.
to demonstrate the benefits of physiotherapy (PT) with pelvic floor biofeedback (BFB) in improving health-related quality of life when used as a complementary therapy after surgical treatment of cystocele, in cases in which perineal pain or discomfort persists.
prospective observational study in 226 women who received complementary therapy after surgical treatment of cystocele due to persistent perineal discomfort or pain. Groups: GA ( = 78): women treated with 25 mg of oral pregabalin every 12 h plus BFB, consisting of 20 once-weekly therapy sessions, each 20 min long, with perineal pregelled surface electrodes connected to a screen which provides visual feedback; GB ( = 148): women treated with oral pregabalin 25 mg every 12 h without BFB.
age, body mass index (BMI), time since onset of cystocele prior to surgery (TO), SF-36 health-related quality of life survey score, diseases and concomitant health conditions, follow-up time, success, or failure of postsurgical treatment.
average age 67.88 years (SD 12.33, 30-88), with no difference between GA and GB. Average body mass index (BMI) 27.08 (SD 0.45, 18.74-46.22), with no difference between GA and GB. Time since onset of cystocele prior to surgery (TO) was 6.61 years (SD 0.6), with no difference between GA and GB. Pretreatment SF-36 score was lower in GA success than GB success. Treatment was successful in 141 (63.20%) women and failed in 82 (36.80%). PT and age were the main predictors of success, and the least important were pretreatment SF-36 and the time elapsed after the intervention. In GA, 63 women (80.80%) showed improvement while 15 (19.20%) did not. Age was the main predictor of treatment success, while the least important was BMI. In GB, 78 women (53.80%) showed improvement while 67 (46.20%) did not improve. The main predictor was time since cystocele onset prior to surgery, while the least important was age. The odds ratio (OR) of improving quality of life for each unit increase in SF-36 was 11.5% (OR = 0.115) in all patients, with no difference between success and failure; in GA it was 23.80% (OR = 0.238), with a difference between success and failure; in GB it was 11.11% (OR = 0.111), with no difference between success and failure. GA and GB success had more history of eutocic delivery. GA success had more rUTI. GB success and GA failure both had more history of UI corrective surgery. The "failure" outcome had a higher number of patients with more than two concomitant pathological conditions.
BFB as an adjunctive treatment improves quality of life in women suffering from persistent discomfort after surgery for cystocele. Young women who meet the criteria for recurrent urinary tract infection or who have a history of eutocic delivery show greater improvement. Body mass index does not influence response to treatment, while the presence of more than two concomitant conditions indicates a poor prognosis for improving quality of life.
证明在膀胱膨出手术治疗后,当会阴疼痛或不适持续存在时,盆底生物反馈(BFB)物理治疗(PT)作为辅助治疗在改善健康相关生活质量方面的益处。
对226名因持续性会阴不适或疼痛在膀胱膨出手术治疗后接受辅助治疗的女性进行前瞻性观察研究。分组:GA组(n = 78):女性患者每12小时口服25毫克普瑞巴林加BFB治疗,包括每周一次,每次20分钟,共20次治疗,使用连接到屏幕的会阴预凝胶表面电极提供视觉反馈;GB组(n = 148):女性患者每12小时口服25毫克普瑞巴林,不进行BFB治疗。
年龄、体重指数(BMI)、手术前膀胱膨出开始的时间(TO)、SF - 36健康相关生活质量调查评分、疾病及伴随健康状况、随访时间、手术治疗的成功或失败。
平均年龄67.88岁(标准差12.33,30 - 88岁),GA组和GB组之间无差异。平均体重指数(BMI)27.08(标准差0.45,18.74 - 46.22),GA组和GB组之间无差异。手术前膀胱膨出开始的时间(TO)为6.61年(标准差0.6),GA组和GB组之间无差异。GA组成功患者的治疗前SF - 36评分低于GB组成功患者。141名(63.20%)女性治疗成功,82名(36.80%)失败。PT和年龄是成功的主要预测因素,最不重要的是治疗前SF - 36评分和干预后经过的时间。在GA组中,63名女性(80.80%)有改善,15名(19.20%)没有改善。年龄是治疗成功的主要预测因素,而最不重要的是BMI。在GB组中,78名女性(53.80%)有改善,67名(46.20%)没有改善。主要预测因素是手术前膀胱膨出开始的时间,而最不重要的是年龄。所有患者中,SF - 36评分每增加一个单位,改善生活质量的优势比(OR)为11.5%(OR = 0.115),成功与失败之间无差异;在GA组中为23.80%(OR = 0.238),成功与失败之间有差异;在GB组中为11.11%(OR = 0.111),成功与失败之间无差异。GA组和GB组成功患者有更多顺产史。GA组成功患者有更多复发性尿路感染。GB组成功患者和GA组失败患者都有更多尿失禁矫正手术史。“失败”结果组中患有两种以上伴随病理状况的患者数量更多。
BFB作为辅助治疗可改善膀胱膨出手术后持续不适女性的生活质量。符合复发性尿路感染标准或有顺产史的年轻女性改善更明显。体重指数不影响治疗反应,而存在两种以上伴随状况表明改善生活质量的预后较差。